BLCO - Bausch + Lomb Corporation Stock Price, Fair Value and News

15.28USD+0.47 (+3.17%)Delayed as of 09 May 2024, 03:01 pm ET

Market Summary

USD15.28+0.47

Delayedas of 09 May 2024, 03:01 pm

3.17%

BLCO Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

BLCO Stock Price

View Fullscreen

BLCO RSI Chart

BLCO Valuation

Market Cap

5.2B

Price/Earnings (Trailing)

-15.45

Price/Sales (Trailing)

1.21

EV/EBITDA

17.73

Price/Free Cashflow

-39.74

BLCO Price/Sales (Trailing)

BLCO Profitability

EBT Margin

-4.66%

Return on Equity

-5.01%

Return on Assets

-2.54%

Free Cashflow Yield

-2.52%

BLCO Fundamentals

BLCO Revenue

Revenue (TTM)

4.3B

Rev. Growth (Yr)

18.05%

Rev. Growth (Qtr)

-6.31%

BLCO Earnings

Earnings (TTM)

-337.0M

Earnings Growth (Yr)

-85.56%

Earnings Growth (Qtr)

-209.26%

Breaking Down BLCO Revenue

52 Week Range

14.9021.95

(Low)(High)

Last 7 days

7.7%

Last 30 days

-9.9%

Last 90 days

6.6%

Trailing 12 Months

-19.6%

How does BLCO drawdown profile look like?

BLCO Financial Health

Current Ratio

1.7

Debt/Equity

0.68

Debt/Cashflow

0.02

BLCO Investor Care

Shares Dilution (1Y)

0.35%

Diluted EPS (TTM)

-0.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.3B	0	0	0
2023	3.8B	3.9B	4.0B	4.1B
2022	3.8B	3.8B	3.8B	3.8B
2021	3.5B	3.6B	3.7B	3.8B
2020	0	0	0	3.4B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Bausch + Lomb Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 24, 2024	stewart andrew j.	sold (taxes)	-58,750	14.9	-3,943	see remarks
Apr 24, 2024	bailey a robert d	sold (taxes)	-146,586	14.9	-9,838	evp & chief legal officer
Mar 29, 2024	robertson russel c	acquired	25,621	17.3	1,481	-
Mar 29, 2024	paulson john	acquired	21,867	17.3	1,264	-
Mar 29, 2024	de schutter richard u	acquired	26,866	17.3	1,553	-
Mar 05, 2024	ling karen	acquired	-	-	2,642	-
Mar 01, 2024	bonnefoy luc	sold (taxes)	-18,084	16.47	-1,098	president,surgical
Mar 01, 2024	hashad yehia	sold (taxes)	-35,295	16.47	-2,143	evp of r&d and cmo
Mar 01, 2024	munsch frederick	sold (taxes)	-16,387	16.47	-995	svp, controller and cao
Mar 01, 2024	eldessouky sam	sold (taxes)	-79,945	16.47	-4,854	evp and cfo

Which funds bought or sold BLCO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	279	516,937	698,643	-%
May 07, 2024	Fore Capital, LLC	new	-	383,714	383,714	0.24%
May 07, 2024	Illinois Municipal Retirement Fund	sold off	-100	-836,000	-	-%
May 07, 2024	CLARK ESTATES INC/NY	added	11.87	1,265,630	10,682,800	1.76%
May 07, 2024	TECTONIC ADVISORS LLC	sold off	-100	-615,464	-	-%
May 06, 2024	Quantbot Technologies LP	sold off	-100	-503,782	-	-%
May 06, 2024	Parallel Advisors, LLC	reduced	-25.00	-4,902	15,570	-%
May 03, 2024	VICTORY CAPITAL MANAGEMENT INC	reduced	-2.1	-70,786	9,702,380	0.01%
May 03, 2024	DAVENPORT & Co LLC	sold off	-100	-2,301,410	-	-%
May 02, 2024	NJ State Employees Deferred Compensation Plan	unchanged	-	6,120	441,150	0.06%

Are Funds Buying or Selling BLCO?

Are funds buying BLCO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BLCO

No. of Funds

Unveiling Bausch + Lomb Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	bausch health companies inc.	88.7%	310,449,643	SC 13G

Recent SEC filings of Bausch + Lomb Corporation

View All Filings

Date Filed	Form Type	Document
May 01, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 07, 2024	3	Insider Trading

Bausch + Lomb Corporation News

Latest updates

Bausch + Lomb Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-6.3%	1,099	1,173	1,007	1,035	931	996	942	941	889	1,001	949	934	881	-
Costs and Expenses	-2.8%	1,093	1,124	967	992	933	945	896	885	835	909	855	876	796	-
S&GA Expenses	4.3%	504	483	418	417	418	386	381	368	343	365	348	358	318	-
EBITDA Margin	2.5%	0.12*	0.12*	0.12*	0.13*	0.14*	0.16*	0.17*	0.18*	0.18*	0.19*	0.20*	0.20*	0.21*	0.21*
Interest Expenses	0%	99.00	99.00	76.00	58.00	50.00	47.00	35.00	44.00	20.00	-	-	-	-	-
Income Taxes	1316.7%	73.00	-6.00	45.00	10.00	33.00	-2.00	34.00	20.00	6.00	32.00	25.00	21.00	47.00	-
Earnings Before Taxes	-57.9%	-90.00	-57.00	-35.00	-19.00	-55.00	-2.00	19.00	27.00	29.00	86.00	88.00	67.00	77.00	-
EBT Margin	-16.4%	-0.05*	-0.04*	-0.03*	-0.01*	0.00*	0.02*	0.04*	0.06*	0.07*	0.08*	0.08*	0.08*	0.08*	0.08*
Net Income	-209.3%	-167	-54.00	-84.00	-32.00	-90.00	-1.00	-18.00	5.00	20.00	51.00	60.00	44.00	27.00	-
Net Income Margin	-24.6%	-0.08*	-0.06*	-0.05*	-0.04*	-0.03*	0.00*	0.02*	0.04*	0.05*	0.05*	0.00*	-0.01*	-0.01*	-0.01*
Free Cashflow	62.3%	-26.00	-69.00	15.00	-51.00	-93.00	109	-22.00	122	-39.00	100	232	205	143	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet										(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-1.1%	13,293	13,442	13,068	11,315	11,169	11,144	10,696	11,002	10,907	10,823
Current Assets	0.0%	2,743	2,742	2,464	2,315	2,184	2,137	1,859	2,001	1,719	1,635
Cash Equivalents	-1.8%	325	331	355	384	346	354	297	446	190	177
Inventory	4.4%	1,073	1,028	754	699	697	628	605	606	598	572
Net PPE	0.5%	1,397	1,390	1,284	1,294	1,296	1,300	1,222	1,243	1,225	1,225
Goodwill	-0.6%	4,547	4,575	23.00	4,540	4,522	4,507	4,415	4,493	4,553	4,586
Liabilities	0.6%	6,564	6,522	6,185	4,285	4,117	4,043	3,901	4,031	3,691	1,421
Current Liabilities	2.4%	1,617	1,579	1,386	1,325	1,254	1,296	1,199	1,273	1,092	1,099
Long Term Debt	0.5%	4,554	4,532	4,435	2,604	2,508	2,411	2,413	2,417	-	-
LT Debt, Current	0%	30.00	30.00	30.00	25.00	25.00	25.00	25.00	25.00	-	-
LT Debt, Non Current	-100.0%	-	4,532	4,435	2,604	2,508	2,411	2,413	2,417	-	-
Shareholder's Equity	-1.8%	6,729	6,850	6,817	7,030	7,052	7,033	6,795	6,971	7,216	9,402
Retained Earnings	-65.7%	-421	-254	-200	-116	-84.00	6.00	7.00	25.00	20.00	-
Additional Paid-In Capital	0.2%	8,363	8,349	8,334	8,321	8,305	8,285	8,108	8,088	8,219	-
Shares Outstanding	0.1%	351	351	351	351	350	350	350	350	350	350
Minority Interest	0%	70.00	70.00	66.00	72.00	69.00	68.00	66.00	75.00	76.00	73.00
Float	-	-	-	-	802	-	-	-	603	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	173.3%	41.00	15.00	48.00	-24.00	-56.00	159	27.00	156	3.00	162	273	250	188	-
Share Based Compensation	18.8%	19.00	16.00	16.00	18.00	24.00	17.00	18.00	11.00	16.00	17.00	16.00	15.00	14.00	-
Cashflow From Investing	57.8%	-57.00	-135	-1,882	-28.00	-64.00	-90.00	-49.00	-35.00	-41.00	-81.00	-40.00	-45.00	-48.00	-
Cashflow From Financing	-86.0%	12.00	86.00	1,811	90.00	91.00	-7.00	-109	145	52.00	-37.00	-378	-183	-114	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BLCO Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues
Total revenues	$ 1,099	$ 931
Expenses
Selling, general and administrative (Note 4)	504	418
Research and development	82	77
Amortization of intangible assets	74	57
Other expense, net	9	9
Total expenses	1,093	933
Operating income (loss)	6	(2)
Interest income	3	3
Interest expense	(99)	(50)
Foreign exchange and other	0	(6)
Loss before provision for income taxes	(90)	(55)
Provision for income taxes	(73)	(33)
Net loss	(163)	(88)
Net income attributable to noncontrolling interest	(4)	(2)
Net loss attributable to Bausch + Lomb Corporation	$ (167)	$ (90)
Basic loss per share attributable to Bausch + Lomb Corporation (in usd per share)	$ (0.48)	$ (0.26)
Diluted loss per share attributable to Bausch + Lomb Corporation (in usd per share)	$ (0.48)	$ (0.26)
Basic weighted-average common shares (in shares)	351.1	350.0
Diluted weighted-average common shares (in shares)	351.1	350.0
Product sales
Revenues
Total revenues	$ 1,094	$ 928
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	423	371
Other revenues
Revenues
Total revenues	5	3
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	$ 1	$ 1

BLCO Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 315	$ 331
Restricted cash	10	3
Trade receivables, net	920	839
Inventories, net	1,073	1,028
Prepaid expenses and other current assets (Note 4)	425	541
Total current assets	2,743	2,742
Property, plant and equipment, net	1,397	1,390
Intangible assets, net	3,515	3,589
Goodwill	4,547	4,575
Deferred tax assets, net	860	921
Other non-current assets (Note 4)	231	225
Total assets	13,293	13,442
Current liabilities:
Accounts payable (Note 4)	426	522
Accrued and other current liabilities	1,161	1,027
Current portion of long-term debt	30	30
Total current liabilities	1,617	1,579
Deferred tax liabilities, net	14	14
Other non-current liabilities	379	397
Long-term debt	4,554	4,532
Total liabilities	6,564	6,522
Commitments and contingencies (Note 17)
Equity
Common shares, no par value, unlimited shares authorized, 351.401653 and 350.913804 issued and outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Additional paid-in capital	8,363	8,349
Accumulated deficit	(421)	(254)
Accumulated other comprehensive loss	(1,283)	(1,245)
Total Bausch + Lomb Corporation shareholders’ equity	6,659	6,850
Noncontrolling interest	70	70
Total equity	6,729	6,920
Total liabilities and equity	$ 13,293	$ 13,442

About Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

CEO	Mr. Brenton L. Saunders J.D.
WEBSITE	bausch.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	13000

Bausch + Lomb Corporation Frequently Asked Questions

What is the ticker symbol for Bausch + Lomb Corporation? What does BLCO stand for in stocks?

BLCO is the stock ticker symbol of Bausch + Lomb Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bausch + Lomb Corporation (BLCO)?

As of Wed May 08 2024, market cap of Bausch + Lomb Corporation is 5.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BLCO stock?

You can check BLCO's fair value in chart for subscribers.

What is the fair value of BLCO stock?

You can check BLCO's fair value in chart for subscribers. The fair value of Bausch + Lomb Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bausch + Lomb Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BLCO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bausch + Lomb Corporation a good stock to buy?

The fair value guage provides a quick view whether BLCO is over valued or under valued. Whether Bausch + Lomb Corporation is cheap or expensive depends on the assumptions which impact Bausch + Lomb Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLCO.

What is Bausch + Lomb Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, BLCO's PE ratio (Price to Earnings) is -15.45 and Price to Sales (PS) ratio is 1.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLCO PE ratio will change depending on the future growth rate expectations of investors.